研究疾病:
|
阿尔茨海默病
|
研究疾病代码:
|
|
Target disease:
|
Alzheimer's disease
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机抽样
Randomly Sampling
|
研究所处阶段:
Study phase:
|
探索性研究/预试验
Pilot clinical trial
|
研究目的:
|
本研究以中医辨证分型为前提,选择符合气阴两虚证的轻、中度AD患者,结合评估量表、核磁共振、脑脊液生物标志物检测或淀粉样蛋白PET扫描及肠道菌群检测,采取随机抽样的方式进行分组,进行6个月的临床研究,探讨抗衰老片对阿尔兹海默病的认知功能的改善或病情延缓作用,以及抗衰老片安全性的评价研究。
|
Objectives of Study:
|
Based on TCM syndrome differentiation and classification, this study selected patients with mild and moderate AD in line with qi-Yin deficiency syndrome, combined with assessment scale, NUCLEAR magnetic resonance, cerebrospinal fluid biomarker detection or amyloid PET scan and intestinal microflora detection, and divided them into groups by random sampling. The clinical study was conducted for 6 months. To explore the effect of anti-aging tablets on improving cognitive function or delaying the disease of Alzheimer's disease, and to evaluate the safety of anti-aging tablets.
|
药物成份或治疗方案详述:
|
|
Description for medicine or protocol of treatment in detail:
|
|
纳入标准:
|
①符合NINCDS-ADRDA很可能的AD痴呆诊断标准,病程≥6个月。
②简易精神状态评价量表(MMSE)(11≤MMSE得分≤26,对于初等教育的受试者,11≤MMSE得分≤24);
③年龄≥65岁,≤85岁,男女不限;
④具有小学及以上文化程度,有能力完成方案规定的测试。
⑤接受全面的神经心理评估;Hachinski 缺血量表≤4分;且汉密尔顿抑郁量表(HAMD)≤10分;
⑥中医辨证分型为气阴两虚的患者;
⑦应有稳定的陪同人员,或每周至少4天,每天2小时与陪同人员联系。陪同人员应在整个试验过程中为患者提供帮助;
⑧神经系统检查无明显阳性体征;
⑨患者及/或家属在知情同意书上签字,并同意按照试验方案的要求参加所有的访视及检查、治疗。
|
Inclusion criteria
|
① Meet the probable diagnostic criteria of NINCDS-ADRDA for AD dementia, and the course of disease is ≥6 months.
② Simplified Mental State Assessment Scale (MMSE) (11≤MMSE score ≤26, 11≤MMSE score ≤24 for primary education);
③ Age ≥65 years old, ≤85 years old, male and female;
④ Have a primary school education or above and have the ability to complete the test required by the program.
⑤ Receive a comprehensive neuropsychological assessment; Hachinski ischemia scale ≤4 points; Hamilton Depression Scale (HAMD) ≤10;
⑥ Patients with deficiency of qi and Yin in TCM syndrome differentiation;
There should be stable accompanying personnel, or at least 4 days a week, 2 hours a day contact with the accompanying personnel. The attendant should assist the patient throughout the trial;No obvious positive signs in neurological examination;
⑨ The patients and/or their family members sign the informed consent and agree to participate in all visits, examinations and treatment in accordance with the requirements of the study protocol.
|
排除标准:
|
①排除其他疾病引起的痴呆,如血管性痴呆、额颞叶痴呆、路易体痴呆等;排除甲状腺疾病、甲状旁腺疾病,酒精中毒、药物中毒、脑肿瘤、正常压力脑积水等;
②抑郁症(HAMD≥17分)所引起的假性痴呆;
③常规实验室研究,包括维生素B12水平、叶酸水平和甲状腺激素水平;定量HIV抗体、梅毒血清学检查等,排除其他因素引起的痴呆患者;
④既往有精神疾病史(如精神分裂症)的患者或影响合作者;
⑤排除癫痫,有酗酒或精神类药物滥用史;
⑥心血管、肺、肝、肾、造血系统等重大躯体疾病急性期的患者;
⑦有磁共振检查禁忌症;
⑧听力及视力严重异常;
⑨中医辨证分型非气阴两虚证者。
|
Exclusion criteria:
|
① Exclude dementia caused by other diseases, such as vascular dementia, frontotemporal dementia, lewy body dementia, etc.; Thyroid disease, parathyroid disease, alcoholism, drug intoxication, brain tumor, normal pressure hydrocephalus, etc.
② Pseudodementia caused by depression (HAMD≥17);
③ Routine laboratory studies, including vitamin B12 levels, folic acid levels and thyroid hormone levels; Quantitative HIV antibody and serological examination of syphilis were performed to exclude dementia patients caused by other factors.
④ patients with a history of mental illness (such as schizophrenia) or influence collaborators;
⑤ Exclude epilepsy, alcohol or psychotropic drug abuse history;
⑥ Acute stage of cardiovascular, lung, liver, kidney, hematopoietic system and other major body diseases;
⑦ There are contraindications to Mr Examination;
⑧ severe abnormalities of hearing and vision;
⑨ TCM syndrome differentiation: non-qi and Yin deficiency syndrome.
|
研究实施时间:
Study execute time:
|
从From
2021-06-01
至To
2023-05-31
|
征募观察对象时间:
Recruiting time:
|
从From
2021-12-24
至To
2022-12-31
|